Food additive is indispensable in food, food manufacturers need to add the food additives in the production process, in order to change the food color, smell, or adjust the taste of food, and for a time, such as Preservatives and antioxidants, and Sweeteners, such as these are most of food additives, plant extracts, through professional technology of extraction, There are many kinds of food additives, mainly: preservatives, colorants, sweeteners, spices, leavening agents, acidity regulators, antioxidants, thickeners, emulsifiers and Food Additives,Tbhq Active Ingredients Powder,Custom Citric Acid,Useful Plant Extractpowers so on. Food Additives,Tbhq Active Ingredients Powder,Custom Citric Acid,Useful Plant Extractpowers Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikang.com
Recently, a research report published in the international journal Cancer Discovery, researchers from the University of Texas MD Anderson Cancer Research Center conducted a first phase of human clinical trials, the first investigation of new types of Whether the experimental drug can effectively treat many types of cancer caused by RET receptor tyrosine kinase changes, the drug seems to be a potential new treatment for RET-driven cancer, such as colorectal cancer, cholangiocarcinoma, non-small A type of cancer that is difficult to treat in lung cancer.
Today, the oral drug, called BLU-667, is being tested in open trials at multiple research centers where the researchers have been inflammatory in the preclinical and early clinical trials. Vivek Subbiah, MD, said that there is an urgent need to develop effective drugs to treat a variety of cancers with RET mutations. However, there are no potent inhibitors approved for the treatment of RET-driven cancer. Confined to traditional chemotherapy and early multi-kinase inhibitors, these therapies have very limited success rates and often have large side effects that can significantly affect a patient's quality of life.
In the article, the researchers investigated whether the drug BLU-667 can be used as a precise targeted drug. Through a proof-of-concept test, BLU-667 has potential viability and can be used as a highly efficient selective RET. Inhibitors work to target cancers that alter RET with fewer side effects and do not affect non-cancerous tissues or organs.
RET almost general medullary thyroid carcinoma, papillary thyroid carcinoma 20% and 1% -2% of non-small cell lung cancer is directly related to, on subsequent researchers Subbiah unsuitable for 43 malignant tumor surgery patients studied, At the same time, 26 patients with medullary thyroid carcinoma, 15 patients with non-small cell lung cancer, and 2 other RET-driven cancer patients were found to have significantly reduced tumors in most patients after using new drugs. And the patient's body's response is more durable, especially in patients with cancer still progressing under the influence of chemotherapy and various kinase inhibitors.
The researchers said that for RET-driven cancer patients, the overall response rate to drugs was 37%, non-small cell lung cancer patients had a response rate of 45%, and thyroid medullary cancer patients had a response rate of 32%. Compared to other types of kinases tested by researchers, BLU-667 is 100 times more selective for RET than the former, and studies have shown that it can effectively block mutations in the "Gatekeeper" gene, which is often associated with cancer. The resistance of kinase therapy is directly related.
Finally, researcher Subbiah said that precise targeted therapy with a new generation of kinase inhibitors can have a significant beneficial effect on the treatment of RET-driven cancer patients, but by tailoring a high choice for the driver of oncogenes Sex drugs, researchers hope that this will bring a certain therapeutic benefit to a variety of cancer patients, and researchers hope that later in-depth research can be carried out to develop more revolutionary treatments for cancer-driven cancer patients.